Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling

Ngoc Tran; Ganessan Kichenadasse; Katherine Morel; Rebecca Ormsby; Lisa M. Butler; Maggie M. Centenera; Pam Sykes

doi:10.1158/1538-7445.AM2016-LB-233

Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling

Ngoc Tran, Ganessan Kichenadasse, Katherine Morel, Rebecca Ormsby, Lisa M. Butler, Maggie M. Centenera, Pam Sykes

Research output: Contribution to journal › Meeting Abstract › peer-review

Abstract

The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.

Original language	English
Article number	Abstract LB-233
Journal	Cancer Research
Volume	76
Issue number	14 Suppl.
DOIs	https://doi.org/10.1158/1538-7445.AM2016-LB-233
Publication status	Published - Jul 2016
Event	AACR 107th Annual Meeting 2016 - Duration: 16 Apr 2016 → …

Keywords

androgen receptor signaling
metformin
personalized prostate cancer treatment
valproic acid
Combination of metformin and valproic acid

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.AM2016-LB-233Licence: In Copyright

Cite this

@article{953caca250c145f98507d9695dde2b31,

title = "Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling",

abstract = "The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.",

keywords = "androgen receptor signaling, metformin, personalized prostate cancer treatment, valproic acid, Combination of metformin and valproic acid",

author = "Ngoc Tran and Ganessan Kichenadasse and Katherine Morel and Rebecca Ormsby and Butler, {Lisa M.} and Centenera, {Maggie M.} and Pam Sykes",

year = "2016",

month = jul,

doi = "10.1158/1538-7445.AM2016-LB-233",

language = "English",

volume = "76",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "14 Suppl.",

note = "AACR 107th Annual Meeting 2016 ; Conference date: 16-04-2016",

}

TY - JOUR

T1 - Combination of metformin and valproic acid in personalized prostate cancer treatment

T2 - AACR 107th Annual Meeting 2016

AU - Tran, Ngoc

AU - Kichenadasse, Ganessan

AU - Morel, Katherine

AU - Ormsby, Rebecca

AU - Butler, Lisa M.

AU - Centenera, Maggie M.

AU - Sykes, Pam

PY - 2016/7

Y1 - 2016/7

N2 - The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.

AB - The anti-diabetic drug Metformin (MET) has been shown to reduce the incidence of prostate cancer, while the anti-epileptic drug Valproic Acid (VPA) has also been shown to have an anti-tumor effect. Here we aimed to determine if the combination of MET and VPA would induce at least an additive anti-tumour effect in prostate cancer due to their different mechanisms of action, and whether common mutations in prostate cancer (e.g. TP53 and AR genes) would affect the response.

KW - androgen receptor signaling

KW - metformin

KW - personalized prostate cancer treatment

KW - valproic acid

KW - Combination of metformin and valproic acid

U2 - 10.1158/1538-7445.AM2016-LB-233

DO - 10.1158/1538-7445.AM2016-LB-233

M3 - Meeting Abstract

SN - 0008-5472

VL - 76

JO - Cancer Research

JF - Cancer Research

IS - 14 Suppl.

M1 - Abstract LB-233

Y2 - 16 April 2016

ER -

Combination of metformin and valproic acid in personalized prostate cancer treatment: the role of p53 and androgen receptor signaling

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this